Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis by L. Cantarini et al.
Yonsei Med J   http://www.eymj.org   Volume 53   Number 5   September 2012 1045
Brief Communication http://dx.doi.org/10.3349/ymj.2012.53.5.1045pISSN: 0513-5796, eISSN: 1976-2437          Yonsei Med J 53(5):1045-1048, 2012
Serum Amyloid A Circulating Levels and Disease Activity  
in Patients with Juvenile Idiopathic Arthritis
Luca Cantarini,1 Teresa Giani,2 Antonella Fioravanti,1 Francesca Iacoponi,3 Gabriele Simonini,2 
Ilaria Pagnini,2 Adriano Spreafico,1 Federico Chellini,1 Mauro Galeazzi,1 and Rolando Cimaz2
1Rheumatology Unit, Department of Clinical Medicine and Immunologic Sciences, University of Siena, Siena;
2Department of Pediatrics, Rheumatology Unit, Anna Meyer Children’s Hospital and University of Florence, Florence;
3Department of Biomedical Sciences, Applied Biology Section, University of Siena, Siena, Italy.
Received: October 27, 2011
Revised: December 6, 2011
Accepted: December 6, 2011
Corresponding author: Dr. Luca Cantarini,
Rheumatology Unit, Department of Clinical 
Medicine and Immunologic Sciences, 
University of Siena, Viale Bracci 1, 
53100 Siena, Italy.  
Tel: 39 347 9385457, Fax: 39 (0) 577 40450
E-mail: cantariniluca@hotmail.com
∙ The authors have no financial conflicts of 
interest.
© Copyright:
Yonsei University College of Medicine 2012
This is an Open Access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
The aim of our study was to evaluate the association between circulating levels of 
serum amyloid A protein (SAA) and disease activity in patients with juvenile idio-
pathic arthritis (JIA). Our study group included 41 JIA patients (9 male, 32 fe-
male), classified according to the International League of Associations for Rheu-
matology (ILAR) criteria (5); 16 had polyarticular onset disease and 25 had 
oligoarticular onset disease. Among 25 patients with oligoarticular disease, three 
had extended oligoarthritis. Serum amyloid A (SAA), erythrocyte sedimentation 
rate (ESR) and C-reactive protein (CRP) were measured in both patients and 26 
healthy controls. SAA levels were higher in JIA patients versus healthy controls 
(p<0.001). Significant positive correlations were found between SAA and the 
presence of active joints (rho=0.363, p<0.05), the number of active joints 
(rho=0.418, p<0.05), ESR (R=0.702, p<0.05) and CRP (R=0.827, p<0.05). No 
significant correlations between ESR and the presence of active joints (rho=0.221, 
p=0.225) or between ESR and the number of active joints (rho=0.118, p=0.520) 
were demonstrated in JIA patients. No significant correlations were obtained be-
tween CRP and the presence of active joints (rho=0.034, p=0.855) or between 
CRP and the number of active joints (rho=0.033, p=0.859). We discovered a sig-
nificant increase in SAA levels in JIA patients, compared to controls, and a strong 
positive correlation between SAA level and JIA disease activity. We also discerned 
SAA to be a more sensitive laboratory marker than ESR and CRP for evaluating 
the presence and number of active joints. We suggest that SAA can be used as an 
additional indicator of disease activity in JIA. 
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In addition to erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), 
there are other known inflammatory markers, such as serum amyloid A protein 
(SAA).1 SAA is an acute-phase reactant transported mainly as an apolipoprotein in 
high-density lipoprotein, and is primarily synthesized in the liver by activated mono-
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Data are summarized as means and standard deviations 
or as medians and interquartile ranges, depending on the 
variable distribution. Comparisons between the control 
group and JIA group were performed using Student’s t-test 
for continuous variables (age and SAA) or the chi-square 
test for qualitative variables (gender). In the JIA group, bi-
variate correlations were calculated using the Pearson corre-
lation coefficient (R) or Spearman’s rho coefficient (rho). 
Comparisons between examined variables were performed 
using the Mann Whitney U-test. 
To evaluate the predictive role of variables with a correla-
tion coefficient greater than 0.5 on dependent variable SAA, 
linear regression analysis was performed. Estimate coeffi-
cients (slope) with a 95% confidence interval (CI 95%) were 
reported. p-values <0.05 (two-tailed) were considered statisti-
cally significant. All analyses were performed using SPSS sta-
tistical package, version 13 (SPSS Inc., Chicago, IL, USA). 
Clinical and demographic characteristics were compara-
ble between patients and controls, except for gender distri-
bution (p<0.02) (Table 1). SAA levels were significantly 
higher in JIA patients versus healthy controls (p<0.001). 
Descriptive statistics and correlation coefficients of all vari-
ables in comparison with SAA are reported in Table 2. Sig-
nificant positive correlations were found between SAA and 
the presence of active joints (rho=0.363, p<0.05), the num-
ber of active joints (rho=0.418, p<0.05), ESR (R=0.702, 
p<0.05) and CRP (R=0.827, p<0.05). No significant corre-
lations were obtained between SAA and JIA duration (R= 
-0.225, p=0.231), JIA type (rho=0.024, p=0.893), BMI (R= 
-0.168, p=0.358) and BMI-SDS (R=-0.052, p=0.776). Also, 
no significant correlations between ESR and the presence 
of active joints (rho=0.221, p=0.225) or between ESR and 
number of active joints (rho=0.118, p=0.520) were demon-
strated in JIA patients. Similarly, no significant correlations 
were obtained between CRP and the presence of active joints 
(rho=0.034, p=0.855) or between CRP and the number of 
active joints (rho=0.033, p=0.859).
Good bivariate correlations between SAA versus ESR 
and CRP variables allowed us to construct a simple linear 
regression model in which SAA was the dependent variable 
and ESR or CRP was the independent variable, in order to 
predict SAA based on any ESR or CRP value. The estimate 
regression coefficients of ESR (slope=6.79, CI 95%: 4.35-
9.23) and CRP (slope=87.56, CI 95%: 66.45-108.66) were 
positive and significant (p<0.001); the regression model 
trend is shown in Fig. 1. 
In vivo SAA serum concentrations may increase dramati-
cytes and macrophages in response to proinflammatory cyto-
kines. Several cytokines, principally interleukin-6 (IL-6), 
IL-1 and tumor necrosis factor (TNF), are involved in the in-
duction of SAA synthesis in hepatocytes.2
SAA has been shown to correlate with disease activity in 
ankylosing spondylitis, and the superiority of SAA to ESR 
and CRP in this regard has recently been suggested.3,4
The aim of our study was to evaluate the association be-
tween circulating levels of SAA and disease activity in pa-
tients with juvenile idiopathic arthritis (JIA).
Our study group included 41 children (9 males, 32 fe-
males) with JIA, classified according to the International 
League of Associations for Rheumatology (ILAR) criteria.5 
Sixteen had polyarticular onset disease and 25 had oligoar-
ticular onset disease. Among 25 patients with oligoarticular 
disease, three had extended oligoarthritis. No patient had 
systemic onset disease. Eleven patients with polyarticular 
and seven with the oligoarticular disease were treated with 
oral methotrexate; 2 patients with oligoarticular disease were 
receiving oral sulphasalazine. The remaining patients were 
treated with nonsteroidal anti-inflammatory drugs only. 
Twenty-six healthy children (14 male, 12 female) attending 
our outpatient clinic (Department of Paediatrics, Rheuma-
tology Unit, Anna Meyer Children’s Hospital, University of 
Florence, Florence, Italy) for musculoskeletal pain and 
without signs of inflammation were enrolled as controls. 
Table 1 summarizes the baseline demographic characteris-
tics and acute phase reactant circulating levels in the JIA 
patients and healthy controls. We excluded subjects who had 
a medical or surgical condition such as recent infection, 
trauma, and/or a neoplastic disease, in order to remove con-
founding factors affecting SAA levels. 
SAA serum concentration was determined by a commer-
cial solid phase sandwich Enzyme linked-immuno-sorbent 
assay (Human SAA; BioSource Europe S.A., Nivelles, Bel-
gium). The assay sensitivity was <4 ng/mL. The normal 
value of  SAA was <10.0 mg/L. 
ESR was measured using the Westergren method, and 
expressed in mm/hour. An ESR of <15 mm/hour was con-
sidered to be normal for males and an ESR of <20 mm/
hour was considered to be normal for females. Serum CRP 
concentrations were measured using a nephelometric im-
munoassay, and expressed in mg/dL. A CRP of <0.5 mg/dL 
was considered to be normal. All the patients were evaluat-
ed for disease duration, different onset types of JIA, body 
mass index (BMI), BMI-standard deviation score (SDS), 
the presence of active joints and number of active joints. 
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The present study attempted to correlate SAA levels with 
disease activity in JIA in comparison to ESR and CRP. Our 
data demonstrated that SAA levels are elevated in JIA pa-
tients, and that they correlate well with disease activity, 
which has only once been previously demonstrated.9 Ac-
cording to Scheinberg, et al.,9 higher SAA levels in children 
cally during acute inflammatory conditions in response to 
inflammatory stimuli, such as IL-1, IL-6 and TNF-α. Sever-
al studies regarding the relationship between SAA level and 
disease activity have been reported in rheumatic diseases 
such as rheumatoid arthritis, polymyalgia rheumatica and 
ankylosing spondylitis.3,4,6-8  
Table 1. Clinical and Demographic Characteristics of Patients 
Characteristics JIA patients Controls p value
No of subjects 41 26
Sex (female/male) 34/7 12/14   0.002
Age (yrs)   6.81 (3.84)   8.84 (4.67)   0.563
BMI (kg/m2) 16.76 (1.82) 17.04 (1.96)   0.554
BMI-SDS   0.08 (0.15)   0.09 (0.21)   0.821
NSAIDs 21 - -
MTX 18 - -
SSZ   2 - -
SAA levels (mg/L)   175.34 (243.83)   42.62 (38.79) <0.001
CRP levels (mg/dL)   1.73 (3.96)   0.37 (0.21) <0.001
ESR levels (mm/h)   24.65 (26.10)   8.37 (5.46) <0.001
JIA, juvenile idiopathic arthritis; BMI, body mass index; SDS, standard deviation score; NSAIDs, nonsteroidal anti-inflammatory drugs; MTX, methotrexate; 
SSZ, sulfasalazine; SAA, serum amyloid A protein; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
Data are summarized as means and standard deviations or as medians and interquartile ranges, depending on the variable distribution.
Table 2. Descriptive Statistics and Correlation Coefficients of All Variables versus SAA
Variable Descriptive statistics Correlations p value
JIA duration (yrs)   1.42 (1.71) -0.225   0.231
JIA type                 4 (3.00-5.00)   0.024   0.893
BMI 16.61 (1.84) -0.168   0.358
BMI-SDS   0.09 (0.99) -0.052   0.776
Presence of active joints (yes/no) 15/17   0.363   0.041
Number of active joints                 0 (0.00-0.00)   0.418   0.017
ESR (mm/h)   24.66 (26.10)   0.702 <0.001
CRP (mg/dL)   1.73 (3.96)   0.827   0.010
SAA, serum amyloid A; JIA, juvenile idiopathic arthritis; BMI, body mass index; SDS, standard deviation score; ESR, erythrocyte sedimentation rate; CRP, 
C-reactive protein. 
Data are summarized as means and standard deviations or as medians and interquartile ranges, depending on the variable distribution.
Fig. 1. Plots with regression lines between SAA and ESR (A) and CRP (B) variables. SAA, serum amyloid A; ESR, erythrocyte sedimentation rate; CRP, 
C-reactive protein. 
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with juvenile rheumatoid arthritis were associated with the 
polyarticular and systemic forms of the disease. In addition, 
SAA levels were correlated with disease activity, increasing 
during acute exacerbations and decreasing during remis-
sion, in patients undergoing prednisone therapy.
According to several reports concerning clinical markers in 
rheumatic disorders, SAA was shown to be superior to CRP 
and ESR with regard to sensitivity and specificity, respective-
ly, and serum levels of SAA are known to reliably indicate 
disease activity.7,10 Included among disease activity scores of 
both clinical and biological parameters, both ESR and CRP 
are now used to evaluate response criteria. In this regard, SAA 
could also prove useful, upon validation by others. 
Both SAA and CRP are produced in the liver, but serum 
levels of the former depend on a larger number of inflam-
matory cytokines, such as IL-1 and IL-6, than those of the 
latter.11,12
The discrepancy between CRP and SAA in JIA patients 
may be explained by the types and amounts of cytokines 
involved. 
In conclusion, we discovered a significant increase in 
SAA levels in JIA patients, compared to controls, and a 
strong positive correlation between SAA level and JIA dis-
ease activity. We also discerned SAA to be a more sensitive 
laboratory marker than ESR and CRP for evaluating the 
presence and number of active joints. Accordingly, we sug-
gest that SAA can be used as an additional indicator of dis-
ease activity in JIA.  
REFERENCES
1. Husby G, Marhaug G, Dowtor B, Sletten K, Sipe JD. Serum amy-
